As of November 6, 2026, Cumberland Pharmaceuticals Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 1, 2026 (Form 8-K, July 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cumberland Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cumberland Pharmaceuticals Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-01. Every row below is cited to the filing it comes from, and this page adds each new change as Cumberland Pharmaceuticals Inc files it.
Also on the record for Cumberland Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 9, 2026 | Stake report, Schedule 13G, by A.J. Kazimi | 38.4% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by Integrated Core Strategies (US) LLC | 4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cumberland Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Cumberland Pharmaceuticals Inc and the records around it.
Companies that share a holder
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
Watch Cumberland Pharmaceuticals Inc
Get an email when Cumberland Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cumberland Pharmaceuticals Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cumberland Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cumberland Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-01 | Reported | not named in the filing | 8-K, 2026-07-01 |
New leaders reset buying decisions — get the Full Report on Cumberland Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Cumberland Pharmaceuticals Inc, with the record behind each one.
Find candidates like senior executive at Cumberland Pharmaceuticals IncEvery change, in the filing's words
Reported
Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.
- As of July 1, 2026, both officers signed offer letters for employment with an affiliate of Apotex.
Tools for this story
Each opens in a new tab, filled in for Cumberland Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.